OCRA is pleased to announce the recipients of two research prizes, selected by members of our Scientific Advisory Committee for their notable contributions to the field of ovarian cancer research and commitment to future discoveries. Dr. Kathleen Cho Awarded Rosalind Franklin Excellence in Ovarian Cancer Research Prize The Rosalind Franklin Excellence in Ovarian Cancer Research … Continued
It’s a new year, and there’s no better time to commit to simple actions that can make a big impact! So simple, that they take between one minute and half an hour to complete. Set OCRA as your AmazonSmile charity of choice. If you’re shopping with Amazon, this is a simple and effective, “set it and … Continued
New study findings not only reveal where the most common ovarian cancer subtype originates in certain patients, but also point to the future possibility of being able to predict who will get the disease. The research, published in Cell Reports, was led by Clive N. Svendsen, PhD, of Cedars-Sinai Medical Center and OCRA’s Scientific Advisory Committee … Continued
Finding ways to minimize the pain caused by ovarian cancer can have a major impact on maximizing the quality of life for those dealing with this illness. Acupuncture is one technique tried by some patients to help manage both the discomfort caused by the disease itself, as well as the side effects of the standard … Continued
OCRA is pleased to announce the offering of an additional four groups to our Staying Connected online support group series. Staying Connected is facilitated by our Patient Support team and meets weekly or monthly, depending on the focus of the group. The meetings provide connection with others who share similar experiences and concerns facing ovarian … Continued
Hereditary breast and ovarian cancer syndrome, known as HBOC, refers to a predisposition to develop cancer that is passed down through the generations of a family. HBOC is inherited in the form of a harmful mutation, or change, in a gene. Having one of these mutations increases the chances of developing ovarian cancer. Most commonly, … Continued
More breakthroughs are on the horizon, as OCRA has awarded grants to 22 dedicated scientists at 15 prestigious medical institutions to enable future ovarian cancer discoveries. With this funding, OCRA grantees aim to answer questions that have vexed the scientific community, building on our collective knowledge and identifying new opportunities for ovarian cancer prevention and … Continued
A randomized trial recently showed that patients with an ovarian cancer recurrence who undergo cytoreductive surgery along with chemotherapy show better survival rates than those who only receive chemotherapy. More than 400 patients were randomized into two groups: 206 were assigned to cytoreductive debulking surgery and chemotherapy, and 201 only had chemotherapy. The median survival rate in … Continued
Dr. Anne van Harten, of the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. With her project, “Targeted MDM2 Degradation as a Novel Treatment for Ovarian Cancer,” Dr. van Harten is designing and testing a new compound to target a … Continued
OCRA grantees Ignacio Vázquez-García, PhD and Sohrab Shah, PhD, of Memorial Sloan Kettering Cancer Center, along with colleagues, have found that distinct mutational processes determine the different mechanisms by which certain ovarian cancer tumors are able to evade the immune system and continue to grow. These learnings may lead the way to future immunotherapeutic approaches that can more … Continued
Dr. Sammy Ferri-Borgogno, of UT MD Anderson Cancer Center, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. With her project, “Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian Cancer,” Dr. Ferri-Borgogno is working to better understand ovarian cancer microenvironments, to find ways to better combat drug resistance. What initially sparked your … Continued
Dr. Arun Kanakkanthara, of Mayo Clinic, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With his project, “Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer,” Dr. Kanakkanthara is investigating ways to overcome tumor resistance to PARP inhibitors, a critical issue in ovarian cancer treatment. What initially sparked your interest in science? Science … Continued
Get email updates about research news, action alerts, and ways to join the fight.
